Greenland Mines Ltd is a biotechnology company developing gene therapies for neurodegenerative disorders. Its primary focus is on innovative gene therapy product candidates, including KLTO-101 aimed at the treatment or prevention of Alzheimer’s disease and KLTO-202 for the treatment and prevention of Lou Gehrig’s disease, also known as amyotrophic lateral sclerosis. The company operates in the pharmaceuticals and biotech sector, targeting critical unmet needs in cancer, cardiovascular, and neurodegenerative conditions through advanced cell and gene therapy platforms. Headquartered in Omaha, Nebraska, Greenland Mines Ltd conducts research and development activities centered on these therapeutic areas, positioning it within the broader landscape of emerging biotech firms advancing genetic medicines for severe diseases.